Reading Time: 2 minutesThis week saw the publication of the Phase 2/3 trial results of the experimental drug cocktail, AMX0035, developed by the pharmaceutical company, Amylyx, and carried
Reading Time: 3 minutesAt last year’s International Symposium on ALS/MND in Perth, Australia, Professor Jeffrey Iliff talked about the glymphatic system (C1 in abstract book) – a series
Reading Time: 5 minutesGuest researcher blog post written by Matthew Nolan. My name is Matthew, I’m currently a post-doctoral researcher at Massachusetts General Hospital and Harvard Medical School in
Reading Time: 4 minutesA systematic review of existing scientific literature, performed by a team of researchers led by Dr Arpan Mehta, MRC/MND Association Lady Edith Wolfson Clinical Fellow
Reading Time: 3 minutesGuest researcher blog post written by Darija Šoltić. Originally from Croatia, I came to the UK to do my PhD in neuroscience, where I worked
Reading Time: 3 minutesA recently published paper, reviewing 15 studies that investigated the effectiveness of riluzole as a treatment for MND in real-time, has suggested that the drug
Reading Time: 4 minutesGuest researcher blog post: My name is Sophie Nyberg and I am a neuroscientist currently working in the Lighthouse COVID-19 testing labs in Alderley Park,
Reading Time: 5 minutesLast Thursday marked an exciting milestone in the search for effective therapies for MND as full results from the early-phase 1/2 trial of Biogen’s tofersen
Reading Time: 4 minutesAlthough ALS is a neurodegenerative disease, researchers are increasingly also interested in events happening outside the brain and spinal cord, in particular whether changes in
Reading Time: 2 minutesGuest researcher blog post written by Elisabeth Jirström: Hi! My name is Elisabeth Jirström and I am a PhD student at Royal College of Surgeons